Fate Therapeutics Announces Termination of Collaboration Agr

Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives

Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

San Diego , California , United States , American , Janssen Collaborationduring , Scott Wolchko , Preclinical Development To Focus On , Janssen Biotech Inc , Nasdaq , American Society Of Hematology , Fate Therapeutics Inc , Operational Runwaythe Company , Nature Communications Cichocki , Co Ltd , Psc Product Platformthe Company , Society For Immunotherapy Of Cancer , Drug Administration , Car Nk Cell Program , Christina Tartagliastern Investor Relations Inc , Exchange Commission , Car Nk Cell Program To Accrue , Cash Equivalents , Operational Runway Provided , Pipeline Prioritization , Five Novel Synthetic Controls Designed , Increase Potency , Extend Functional Persistence , Reduce Patient Conditioning , Hematologic Malignancies , Severe Autoimmune Disorders , Accrue Patients , Multi Dose Treatment Cohorts , Enable Dual Antigen Targeting , Mitigate Risk , Selectively Depleting Activated Host Immune , Ono Collaboration Planned , Product Candidate , Promote Effector Cell Function , Immunosuppressive Tumor , Continue Dose , Dose Schedule Optimization , Novel Split Dose Treatment Schedules , Compare Pharmacokinetic , Janssen Biotech , Chief Executive Officer , American Society , Annual Meeting , Investigational New Drug , Accrue Higher Dose , Multi Dose Treatment , Nature Communications , Assessing Single Dose , Novel Split Dose Treatment , Multi Antigen Targeted , Fate Therapeutic , Platformthe Company , Fate Therapeutics , Inc Fate Therapeutics , Looking Statementsthis , Private Securities Litigation Reform Act , Christina Tartagliastern Investor Relations ,